MI

Miromatrix Medical IncNASDAQ MIRO Stock Report

Last reporting period 30 Sep, 2023

Updated —

Last price

Market cap $B

0.093

Micro

Exchange

XNAS - Nasdaq

MIRO Stock Analysis

MI

Uncovered

Miromatrix Medical Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-18/100

Low score

Market cap $B

0.093

Dividend yield

Shares outstanding

27.233 B

Miromatrix Medical Inc. a life sciences company. The Company is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreases. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. The Company's product pipeline includes miroliver, mirokidney, miroheart, mirolung and miropancreas.

View Section: Eyestock Rating